Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

41. Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 22, 2019 Project Number: RC1102-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intraoperative imaging with mammography for breast cancer surgery? What is the cost-effectiveness of intraoperative imaging with mammography for breast cancer surgery? What are the evidence-based guidelines regarding intraoperative imaging

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

42. Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines

was performed, and not for women with a preoperative diagnosis of DCIS who are having breast-conserving surgery, unless they are considered to be at high risk of invasive disease. SLNB is recommended for women who have operable breast cancer who have multicentric tumors, prior breast and/or axillary surgery, or preoperative or neoadjuvant systemic therapy. SLNB, rather than full axillary nodal clearance, is the standard of care in patients with primary breast cancer. The use of SLNB is recommended after (...) Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding methods for sentinel lymph node biopsy for the management of breast cancer? Key Message Five evidence-based guidelines were identified. SLNB is recommended for axillary staging for patients with early-stage or invasive breast cancer without clinically or pathologically positive lymph nodes. SLNB is recommended in patients with ductal carcinoma in situ (DCIS) when mastectomy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

43. Quantitative Image Analysis of HER2 IHC for Breast Cancer

Quantitative Image Analysis of HER2 IHC for Breast Cancer CAP Laboratory Improvement Programs Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer Guideline From the College of American Pathologists Marilyn M. Bui, MD, PhD; Michael W. Riben, MD; Kimberly H. Allison, MD; Elizabeth Chlipala, BS, HTL(ASCP)QIHC; Carol Colasacco, MLIS, SCT(ASCP); Andrea G. Kahn, MD; Christina Lacchetti, MHSc; Anant Madabhushi, PhD; Liron Pantanowitz, MD (...) (IHC) for breast cancer where QIA is used. Design.—The College of American Pathologists (CAP) convened a panel of pathologists, histotechnologists, and computer scientists with expertise in image analysis, immunohistochemistry, quality management, and breast pathology to develop recommendations for QIA of HER2 IHC in breast cancer. A systematic review of the literature was conducted to address 5 key questions. Final recom- mendations were derived from strength of evidence, open comment feedback

2019 College of American Pathologists

44. Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review

Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review | CADTH.ca Find the information you need Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Last updated: May 3, 2019 Project Number: RC1104-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the experiences and perspectives of breast cancer patients, their caregivers and their health care providers with respect to breast cancer surgical care in rural areas? To ensure the relevance of the analysis to the objectives of the primary research question, a secondary set of research questions was explored during data extraction and analysis:a) How do people with breast cancer, and their families, experience travelling for breast cancer surgical care?b) What is the meaning and impact of receiving breast

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

45. Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details | CADTH.ca Find the information you need Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Project Number pCODR 10182 Brand Name Kadcyla Generic Name Trastuzumab Emtansine Tumour Type Breast Indication Early Breast Cancer (EBC) Funding Request For the adjuvant (...) treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy. Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Hoffmann-La Roche Limited Sponsor Hoffmann-La Roche Limited

2019 CADTH - Pan Canadian Oncology Drug Review

46. Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details

Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10195 Brand Name Kisqali Generic Name Ribociclib with Fulvestrant Tumour Type Breast Indication Advanced or Metastatic Breast (...) Cancer Funding Request In combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial therapy or following disease progression on endocrine therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type New Indication

2019 CADTH - Pan Canadian Oncology Drug Review

47. Kisqali for Advanced or Metastatic Breast Cancer – Details

Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10194 Brand Name Kisqali Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request In combination with an aromatase inhibitor (AI) and a luteinizing (...) hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type

2019 CADTH - Pan Canadian Oncology Drug Review

48. Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details

/14 mL & 1200 mg/20 mL Tumour Type Breast Indication Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Funding Request In combination with nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1, and who have not received prior chemotherapy for metastatic disease. Maintenance TECENTRIQ should be continued until disease progression or unacceptable toxicity. Review Status Open (...) Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details | CADTH.ca Find the information you need Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Project Number pCODR 10171 Brand Name Tecentriq Generic Name Atezolizumab Strength 840 mg

2019 CADTH - Pan Canadian Oncology Drug Review

49. Nerlynx for Hormone Receptor-Positive Breast Cancer – Details

Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details | CADTH.ca Find the information you need Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Project Number pCODR 10172 Brand Name Nerlynx Generic Name Neratinib Strength 40 mg Tumour Type Breast Indication Hormone Receptor-Positive Breast Cancer Funding Request For patients with HER2-positive, hormone (...) receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date July 16, 2019 Manufacturer Knight Therapeutics Inc. Sponsor Knight Therapeutics Inc. Submission Date April 18, 2019 Submission Deemed Complete May 3, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ May 3, 2019 Check-point meeting July 4, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

50. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) : Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: June 11, 2019 Project Number: RB1351-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer diagnosis? What is the diagnostic accuracy of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

52. SSO/ASTRO/ASCO Consensus Guideline on Margins for Breast Conserving Surgery (BCS) with Whole Breast Irradiation in Ductal Carcinoma in Situ (DCIS) Full Text available with Trip Pro

rates of ipsilateral breast tumor recurrence (IBTR), even among patients with smaller, non–high-grade DCISs. x [1] Correa, C, McGale, P, Taylor, C et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr . 2010 ; 2010 : 162–177 | | | , x [4] McCormick, B, Winter, K, Hudis, C et al. RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol . 2015 ; 33 : 709 (...) , and tumor factors such as histologic pattern, comedo necrosis, and nuclear grade and size of DCIS also modify the risk of IBTR. x [18] Fisher, ER, Costantino, J, Fisher, B et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Intraductal carcinoma (ductal carcinoma in situ): The National Surgical Adjuvant Breast and Bowel Project collaborating investigators. Cancer . 1995 ; 75 : 1310–1319 | | | , x [27] Bijker, N, Meijnen, P, Peterse, JL et al. Breast

2019 American Society for Radiation Oncology

53. Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original

2019 Health Canada - Drug and Health Product Register

54. Triptorelin acetate (Decapeptyl) - breast cancer

or ovarian irradiation. The latter two methods could be performed initially or after triptorelin had been administered for some time in SOFT and after at least 6 months of triptorelin in TEXT. 3 In both studies the primary outcome was disease-free survival (DFS), defined as the time from randomisation to the first invasive recurrence of breast cancer at local, regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) malignancy; or a death. This was assessed (...) (Prostap SR DCS®and Prostap 3 DCS ®) is indicated as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy. 6 It was licensed in May 2019 and has not been reviewed by SMC. The type of adjuvant

2019 Scottish Medicines Consortium

55. Pertuzumab (Perjeta) - HER2-positive early breast cancer

disease recurrence, or unmanageable toxicity, whichever occurs first) as part of a complete regimen for early breast cancer and regardless of the timing of surgery. Treatment should include standard anthracycline- and/or taxane-based chemotherapy. Pertuzumab and trastuzumab should start on Day 1 of the first taxane-containing cycle and should continue even if chemotherapy is discontinued. Patients must have HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC (...) process pertuzumab (Perjeta®) is not recommended for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease- free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature. The submitting

2019 Scottish Medicines Consortium

56. Abemaciclib for advanced or metastatic Breast Cancer – Details

Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details | CADTH.ca Find the information you need Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details Project Number pCODR 10161 Brand Name Verzenio Generic Name Abemaciclib Strength 50 mg, 100 mg, 150 mg and 200 mg Tumour Type Breast Indication Advanced or metastatic breast cancer Funding Request (...) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist. Review Status Notification to Implement Issued Pre Noc Submission Yes

2019 CADTH - Pan Canadian Oncology Drug Review

57. Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10150 Brand Name Ibrance (with Faslodex) Generic Name Palbociclib (with Fulvestrant) Strength 75 mg, 100 mg & 125 mg Tumour Type Breast (...) Indication Advanced or Metastatic Breast Cancer Funding Request In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist Review Status Notification to Implement Issued Pre Noc Submission No NOC Date May

2019 CADTH - Pan Canadian Oncology Drug Review

58. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

or docetaxel, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin / the treatment of patients with MBC whose tumours overexpress HER2 / in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease Review Status Withdrawn Clarification Mylan Canada has (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

59. Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Project Number pCODR 10160 Brand Name TBD Generic Name Trastuzumab Strength Tumour Type Breast & Gastrointestinal Indication Breast and Gastric Cancer Biosimilar Funding Request Breast and Gastric Cancer

2019 CADTH - Pan Canadian Oncology Drug Review

60. Metastatic Breast Cancer Summary

Metastatic Breast Cancer Summary Metastatic breast cancer Breast cancer is the most common cancer diagnosed in Australia. Approximately 5% of patients diagnosed with breast cancer in Australia have metastatic disease at initial breast cancer diagnosis (NCCI, Cancer Australia), and some patients who have early breast cancer at diagnosis will have a recurrence that is metastatic. However exact statistics on patients with metastatic breast cancer in Australia are not currently available (...) and practical challenges and needs specific to metastatic breast cancer that are important to address. Issues include managing symptoms of metastatic disease and its treatment, adjusting to living with metastatic breast cancer and coping with concerns about facing an uncertain future. Multidisciplinary care is particularly important for patients with metastatic breast cancer due to their complex management and supportive care needs. Effective, sensitive communication in a culturally safe environment

2019 Cancer Australia